Skip to content

Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx

A Pilot Study Assessing the Use of DA VINCI® Robotic Surgical System in Laryngeal and Pharyngeal Surgeries

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00918762
Enrollment
6
Registered
2009-06-11
Start date
2009-05-31
Completion date
2010-10-31
Last updated
2014-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer, Perioperative/Postoperative Complications, Precancerous Condition

Keywords

perioperative/postoperative complications, precancerous condition, stage I squamous cell carcinoma of the hypopharynx, stage II squamous cell carcinoma of the hypopharynx, stage III squamous cell carcinoma of the hypopharynx, stage I squamous cell carcinoma of the larynx, stage I verrucous carcinoma of the larynx, stage II squamous cell carcinoma of the larynx, stage II verrucous carcinoma of the larynx, stage III squamous cell carcinoma of the larynx, stage III verrucous carcinoma of the larynx, stage I lymphoepithelioma of the nasopharynx, stage I squamous cell carcinoma of the nasopharynx, stage II lymphoepithelioma of the nasopharynx, stage II squamous cell carcinoma of the nasopharynx, stage III lymphoepithelioma of the nasopharynx, stage III squamous cell carcinoma of the nasopharynx, stage I lymphoepithelioma of the oropharynx, stage I squamous cell carcinoma of the oropharynx, stage II lymphoepithelioma of the oropharynx, stage II squamous cell carcinoma of the oropharynx, stage III lymphoepithelioma of the oropharynx, stage III squamous cell carcinoma of the oropharynx

Brief summary

RATIONALE: Transoral robotic surgery may make it easier to find and remove benign or malignant tumors of the larynx and pharynx and cause less damage to normal tissue. It is not yet known whether transoral robotic surgery is more effective than standard surgery in diagnosing and treating larynx and pharynx tumors. PURPOSE: This phase I trial is studying how well transoral robotic surgery works compared with standard surgery in treating patients with benign or malignant tumors of the larynx or pharynx.

Detailed description

OBJECTIVES: Primary * Evaluate the potential benefits of using the transoral robotic surgical approach against the conventional open and transoral approaches in patients with benign or malignant disease involving the larynx and pharynx. Secondary * Determine the proportion of laryngeal and pharyngeal surgical procedures where the surgical exposure is adequate to allow the successful completion of the surgical resection using the transoral robotic surgical approach. OUTLINE: Patients are assigned to transoral robotic surgery or standard therapy consisting of conventional transoral endoscopic or open approach according to their preference. Patients undergo planned surgical procedures (either diagnostic or therapeutic) appropriate for their disease in the larynx or pharynx via the transoral robotic surgical approach or the conventional transoral endoscopic or open approach. Patients complete the Functional Assessment of Cancer Therapy Head and Neck Scale, the Performance Status Scale for Head and Neck Cancer Patients, and the University of Washington Quality of Life Scale at baseline and at 3 and 6 months. Patients also undergo voice analysis by acoustic analyses, and speech and swallow pathology evaluation by videostroboscopy and modified barium swallow. After completion of study procedure, patients are followed at 3 and 6 months. PROJECTED ACCRUAL: A total of 80 patients will be accrued to the control group (standard conventional surgery) and 30 patients will be accrued to the robotic surgery group.

Interventions

PROCEDUREassessment of therapy complications
PROCEDUREdiagnostic endoscopic surgery
PROCEDUREquality-of-life assessment
PROCEDUREtherapeutic conventional surgery

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Barbara Ann Karmanos Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Benign or malignant disease of the larynx or pharynx that requires surgical intervention for either diagnostic or therapeutic purposes * Malignant disease must meet the following criteria: * Histologically confirmed diagnosis of 1 of the following: * Glottic cancer (T1, T2, and T3) * Supraglottic cancer (T1, T2, and T3) * Hypopharyngeal cancer (T1 and T2) * Oropharyngeal cancer (T1, T2, and T3) * Nasopharyngeal cancer (T1 and T2) * Resectable involved lymph nodes * No invasion of osseous and/or osseocartilaginous structures including the following: * Mandibular bone * Thyroid cartilage * Hyoid bone * Cricoid bone * Vertebral body * No pharyngeal wall or tongue-based involvement requiring resection of \> 50% of the posterior pharyngeal wall or tongue base * No radiological confirmation of carotid artery involvement * No fixation of tumor to the prevertebral fascia * No bilateral arytenoid involvement * No surgical defect requiring open approach for reconstruction * No evidence of distant metastasis PATIENT CHARACTERISTICS: * Not pregnant * No unexplained fever and/or untreated active infection * No medical conditions contraindicating general anesthesia * No inadequate jaw opening due to prior head and neck surgery, trauma, or radiotherapy PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

MeasureTime frame
Operative time that directly affects operative costpost operative

Secondary

MeasureTime frame
Intra-operative and post-operative complicationsduring the operation and post operative
Need for reconstructionpost operative
Margins statuspost operative
Length of hospital stayduring time as inpatient
Tracheostomy and PEG dependencepost operative
Blood lossDuring surgery
Time to locoregional recurrencepost operative
Speech intelligibilitypost operative
Quality of life3 months and 6 month following completion of surgery
Postoperative painpost operative
Proportion of robotic surgical cases where adequate surgical exposure allowed for successful operation completionpost operative
Days to oral intakepost operative

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026